# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, DC 20549** 

### **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

## Achieve Life Sciences, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share (Title of Class of Securities)

<u>004468203</u> (CUSIP Number)

<u>December 31, 2020</u> (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see	the Notes).
CUSIP No. 004468203	
NAME OF REPORTING PERSONS     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
Pura Vida Master Fund, Ltd.	
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) [ ] (b) [X]
3. SEC USE ONLY	(b) [A]
4. CITIZENSHIP OR PLACE OF ORGANIZATION	
Cayman Islands	
5. SOLE VOTING POWER  NUMBER OF SHARES BENEFICIALLY ONLY FOR POWER  65,000	
OWNED BY EACH 7. SOLE DISPOSITIVE POWER REPORTING	
PERSON WITH  0  8. SHARED DISPOSITIVE POWER	
65,000	
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
65,000	
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCT	TONS)
	[]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
1.11%	

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
	00					
CUSIP	P.No. 004468203					
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	Pura Vida Investments, LLC					
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) [ ]				
		(b) [X]				
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	5. SOLE VOTING POWER	_				
NI	JMBER OF 0					
5	SHARES 6. SHARED VOTING POWER					
	WEFICIALLY WNED BY  83,333					
DE	EACH 7. SOLE DISPOSITIVE POWER EPORTING					
	RSON WITH 0 8. SHARED DISPOSITIVE POWER					
9.	83,333 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
10.	83,333 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
		r 1				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	[]				
	1.42%					
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
	IA					
CUSIP	P.No. 004468203					
1.	NAME OF REPORTING PERSONS					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	Efrem Kamen					
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	(a) [ ]				
		(b) [X]				
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	United States of America					
	5. SOLE VOTING POWER					
	0					
	JMBER OF 6. SHARED VOTING POWER SHARES					
BEN	NEFICIALLY 83,333					
O\	WNED BY 7. SOLE DISPOSITIVE POWER EACH					
	EPORTING 0 RSON WITH 8 SHARED DISPOSITIVE POWER					
1 LIN	RSON WITH 8. SHARED DISPOSITIVE POWER					
	83,333					
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	83,333					

10.	CHE	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11.	PERG	CEN	T OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	1.42%						
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	IN, H	IC					
CUSIP N	Jo (	0044	68203				
Item 1.			). Name of Issuer:				
	`		Achieve Life Sciences, Inc.				
	(	1	Address of issuer's principal executive offices:				
	`		1040 West Georgia Street, Suite 1030, Vancouver, B.C. V6E 4H1				
Item 2.	(	Į.	Name of person filing:				
	·		Pura Vida Master Fund, Ltd. Pura Vida Investments, LLC Efrem Kamen				
		•	Address or principal business office or, if none, residence:				
	(		Pura Vida Master Fund, Ltd. c/o Pura Vida Investments, LLC 150 East 52nd Street Suite 32001 New York, New York 10022				
			Pura Vida Investments, LLC 150 East 52 <sup>nd</sup> Street Suite 32001 New York, New York 10022				
			Efrem Kamen c/o Pura Vida Investments, LLC				
			150 East 52 <sup>nd</sup> Street Suite 32001 New York, New York 10022				
	(	(c).	Citizenship:				
			Pura Vida Master Fund, Ltd. – Cayman Islands exempted company Pura Vida Investments, LLC – Delaware limited liability company Efrem Kamen – United States of America				
	(	(d).	Title of class of securities:				
			Common Stock, par value \$0.001 per share				
			CUSIP No.:				
	(	(e).	004468203				
Item 3.	If7		is Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a				
	(	(a)	[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).				
	(	(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).				
	(	(c)	[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).				
	(	(d)	[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).				
	(	(e)	[ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);				
	(	(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);				
	(	(g)	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);				
	(	(h)	[ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);				

	(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (180a-3);						
	(j)	[ ] A	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);				
	(k)		Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in according institution:	ordance with §240.13d-1(b)(1)(ii)(J), please specify the type			
tem 4.	Ownership.						
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.						
	(a) Amount beneficially owned:						
	Pura Vida Investments, LLC – 83,333 shares of Common Stock*						
			Kamen – 333 shares of Common Stock*				
	(b)	Percent	of class:				
		Pura Vi	ida Master Fund, Ltd. – 1.11%* ida Investments, LLC – 1.42%* Kamen – 1.42%*				
	(c)						
		(i)	Sole power to vote or to direct the vote	0			
		(ii)	Shared power to vote or to direct the vote	65,000 shares of Common Stock*			
		(iii)	Sole power to dispose or to direct the disposition of	0			
		(iv) Number	Shared power to dispose or to direct the disposition of r of shares as to which Pura Vida Investments, LLC has:	65,000 shares of Common Stock*			
		(i)	Sole power to vote or to direct the vote	<u>0</u> ,			
		(ii)	Shared power to vote or to direct the vote	83,333 shares of Common Stock*			
		(iii)	Sole power to dispose or to direct the disposition of	0			
		(iv)	Shared power to dispose or to direct the disposition of	83,333 shares of Common Stock*			
		Number	r of shares as to which Efrem Kamen has:				
		(i)	Sole power to vote or to direct the vote	0			
		(ii)	Shared power to vote or to direct the vote	83,333 shares of Common Stock*			
		(iii)	Sole power to dispose or to direct the disposition of	0			
		(iv)	Shared power to dispose or to direct the disposition of	83,333 shares of Common Stock*			

By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Pura Vida Master Fund and the Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Person's pecuniary interest therein.

The percentages herein are calculated based upon (i) a statement in the Issuer's Prospectus filed on December 4h, 2020 that there were 5,766,414 shares of Common Stock issued and outstanding, plus (ii) 83,333 shares of Common Stock issuable upon conversion of the Reporting Person's warrants, for a total of 5,859,747 Common Stock outstanding.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

Pura Vida Master Fund, Ltd.

By: /s/ Efrem Kamen
Name: Efrem Kamen
Title: Director

Pura Vida Investments, LLC

By: <u>/s/ Efrem Kamen</u>
Name: Efrem Kamen
Title: Managing Member

/s/ Efrem Kamen

Efrem Kamen

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

### Joint Filing Statement

#### Statement Pursuant to Rule 13d-1(k)(1)

The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value \$0.001 per share, of Achieve Life Sciences, Inc., beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

Dated: February 16, 2021

Pura Vida Master Fund, Ltd.

By: /s/ Efrem Kamen
Name: Efrem Kamen
Title: Director

Pura Vida Investments, LLC

By: /s/ Efrem Kamen
Name: Efrem Kamen
Title: Managing Member

/s/ Efrem Kamen

Efrem Kamen